Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619873 | 1.00 | CYP2D6 (0.35) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL14046970 | 0.84 | ALDH1A1 (0.37) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL4443279 | 0.84 | ALDH1A1 (0.37) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL12134880 | 0.84 | ALDH1A1 (0.37) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL4620711 | 0.82 | AQP1 (0.39) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL4622612 | 0.82 | MAPT (0.32) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL4621846 | 0.82 | CA12 (0.33) | CA12CA9 | |
| SCHEMBL4622621 | 0.82 | MAPT (0.32) | CYP2D6ALDH1A1CYP3A4TSHRCYP2C9 | |
| SCHEMBL4621419 | 0.81 | AQP1 (0.32) | MAPT | |
| SCHEMBL4621421 | 0.81 | AQP1 (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-07-31 | — | — | US | disclosed |
| US-7365095-B2 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | WYETH (US) | 2006-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182891-A1 | CHROMANE AND CHROMENE DERIVATIVES AND USES THEREOF | HTR1A, HTR2C, CHRM1 | CYP2D6 655/4885ALDH1A1 2512/4885CYP3A4 340/4885 |
| US-20060258714-A1 | Chromane and chromene derivatives and uses thereof | HTR1A, HTR2C, CHRM1 | CYP2D6 655/4885ALDH1A1 2512/4885CYP3A4 340/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.